[SCHEDULE 13G] AnaptysBio, Inc. SEC Filing
Morgan Stanley and its subsidiary Morgan Stanley Capital Services LLC filed a Schedule 13G on 08/05/2025 disclosing a combined passive stake of 1,845,002 ANAB shares (6.3 % of outstanding) as of 06/30/2025. The parent company reports shared voting power over 1,841,919 shares and shared dispositive power over 1,845,002 shares; it holds no sole voting or dispositive authority.
The subsidiary individually owns 1,525,502 shares (5.2 %) with fully shared voting and dispositive power. The filing is made under Rule 13d-1(b), classifying Morgan Stanley as a parent holding company/control person (HC, CO) and the subsidiary as a broker-dealer (BD, CO). Both certify the shares were acquired in the ordinary course of business and not for the purpose of influencing control of AnaptysBio.
Morgan Stanley e la sua controllata Morgan Stanley Capital Services LLC hanno presentato un Schedule 13G il 05/08/2025, dichiarando una partecipazione passiva combinata di 1.845.002 azioni ANAB (6,3% del capitale sociale) al 30/06/2025. La societ脿 madre riporta un potere di voto condiviso su 1.841.919 azioni e un potere dispositive condiviso su 1.845.002 azioni; non detiene alcun potere di voto o dispositive esclusivo.
La controllata possiede individualmente 1.525.502 azioni (5,2%) con poteri di voto e dispositive pienamente condivisi. La comunicazione 猫 stata effettuata secondo la Regola 13d-1(b), classificando Morgan Stanley come societ脿 madre/controllore (HC, CO) e la controllata come broker-dealer (BD, CO). Entrambe certificano che le azioni sono state acquisite nell鈥檕rdinaria attivit脿 aziendale e non con l鈥檌ntento di influenzare il controllo di AnaptysBio.
Morgan Stanley y su subsidiaria Morgan Stanley Capital Services LLC presentaron un Schedule 13G el 05/08/2025, revelando una participaci贸n pasiva combinada de 1,845,002 acciones ANAB (6,3% del total en circulaci贸n) al 30/06/2025. La empresa matriz reporta poder de voto compartido sobre 1,841,919 acciones y poder dispositive compartido sobre 1,845,002 acciones; no posee autoridad exclusiva de voto ni dispositiva.
La subsidiaria posee individualmente 1,525,502 acciones (5,2%) con poder de voto y dispositive completamente compartido. La presentaci贸n se realiza bajo la Regla 13d-1(b), clasificando a Morgan Stanley como empresa matriz/persona controladora (HC, CO) y a la subsidiaria como broker-dealer (BD, CO). Ambas certifican que las acciones fueron adquiridas en el curso ordinario de negocios y no con el prop贸sito de influir en el control de AnaptysBio.
氇贝 鞀ろ儬毽�鞕� 攴� 鞛愴殞靷� Morgan Stanley Capital Services LLC電� 2025雲� 8鞗� 5鞚检棎 Schedule 13G毳� 鞝滌稖頃橃棳 2025雲� 6鞗� 30鞚� 旮办 齑� 1,845,002 ANAB 欤检嫕鞚� 靾橂彊鞝� 氤挫湢 歆�攵�(鞝勳泊 氚滍枆 欤检嫕鞚� 6.3%)鞚� 瓿店皽頄堨姷雼堧嫟. 氇殞靷� 旄§潃 1,841,919欤检棎 雽�頃� 瓿惦彊 鞚橁舶甓�瓿� 1,845,002欤检棎 雽�頃� 瓿惦彊 觳橂秳甓�鞚� 氤搓碃頄堨溂氅�, 雼弲 鞚橁舶甓岇澊雮� 觳橂秳甓岇潃 氤挫湢頃橃 鞎婌姷雼堧嫟.
鞛愴殞靷姅 臧滊硠鞝侅溂搿� 1,525,502欤�(5.2%)毳� 鞕勳爠頌� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇溂搿� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞚措矆 鞝滌稖鞚� 攴滌箼 13d-1(b)鞐� 霐半澕 鞚措（鞏挫鞙茧┌, 氇贝 鞀ろ儬毽姅 氇殞靷�/韱奠牅鞛�(HC, CO)搿�, 鞛愴殞靷姅 欷戧皽-霐滊煬(BD, CO)搿� 攵勲霅╇媹雼�. 鞏戩浮鞚� 頃措嫻 欤检嫕鞚� 鞝曥儊鞝侅澑 靷梾 瓿检爼鞐愳劀 旆摑霅橃棃鞙茧┌ AnaptysBio鞚� 歆�氚瓣秾鞐� 鞓來枼鞚� 氙胳箻旮� 鞙勴暅 氇╈爜鞚� 鞎勲嫎鞚� 歃濍獏頃╇媹雼�.
Morgan Stanley et sa filiale Morgan Stanley Capital Services LLC ont d茅pos茅 un Schedule 13G le 05/08/2025, d茅clarant une participation passive combin茅e de 1 845 002 actions ANAB (6,3 % des actions en circulation) au 30/06/2025. La soci茅t茅 m猫re rapporte un pouvoir de vote partag茅 sur 1 841 919 actions et un pouvoir discr茅tionnaire partag茅 sur 1 845 002 actions ; elle ne d茅tient aucun pouvoir de vote ou discr茅tionnaire exclusif.
La filiale d茅tient individuellement 1 525 502 actions (5,2 %) avec un pouvoir de vote et discr茅tionnaire enti猫rement partag茅. Le d茅p么t est effectu茅 en vertu de la r猫gle 13d-1(b), classant Morgan Stanley comme soci茅t茅 m猫re/personne contr么lante (HC, CO) et la filiale comme courtier-n茅gociant (BD, CO). Les deux certifient que les actions ont 茅t茅 acquises dans le cours normal des affaires et non dans le but d鈥檌nfluencer le contr么le d鈥橝naptysBio.
Morgan Stanley und seine Tochtergesellschaft Morgan Stanley Capital Services LLC haben am 05.08.2025 einen Schedule 13G eingereicht, in dem sie einen kombinierten passiven Anteil von 1.845.002 ANAB-Aktien (6,3 % der ausstehenden Aktien) zum 30.06.2025 offenlegen. Die Muttergesellschaft meldet gemeinsames Stimmrecht 眉ber 1.841.919 Aktien und gemeinsames Verf眉gungsrecht 眉ber 1.845.002 Aktien; sie besitzt keine alleinigen Stimm- oder Verf眉gungsrechte.
Die Tochtergesellschaft h盲lt einzeln 1.525.502 Aktien (5,2 %) mit vollst盲ndig gemeinsamem Stimm- und Verf眉gungsrecht. Die Meldung erfolgt gem盲脽 Regel 13d-1(b) und klassifiziert Morgan Stanley als Muttergesellschaft/Kontrollperson (HC, CO) und die Tochtergesellschaft als Broker-Dealer (BD, CO). Beide best盲tigen, dass die Aktien im normalen Gesch盲ftsverlauf erworben wurden und nicht zum Zweck der Kontrolle von AnaptysBio.
- Morgan Stanley now holds 6.3 % of ANAB鈥檚 outstanding shares, introducing a prominent institutional investor and potential liquidity support.
- Filing is passive (Rule 13d-1(b)), indicating no immediate risk of activist pressure while still signalling confidence in the company.
- None.
Insights
TL;DR 鈥� Morgan Stanley reveals 6.3 % passive stake, adding a high-profile institutional holder to ANAB鈥檚 register.
Morgan Stanley鈥檚 aggregate ownership crosses the 5 % threshold, triggering this 13G. A globally recognised financial institution taking a >6 % position can boost market confidence, increase trading liquidity and widen sell-side coverage for AnaptysBio. Because the filing is passive (13G, not 13D), no immediate strategic activism is implied. Still, passive stakes by sophisticated investors are often viewed positively by the market, especially for mid-cap biotechs that rely on external capital. The reported holding date (30 Jun 2025) precedes the filing by just over a month, so the data are relatively current. Impact: modestly positive.
TL;DR 鈥� No control intent signalled; governance impact minimal.
The 13G certification states the shares were not bought to influence control, and Morgan Stanley claims only shared voting/dispositive power. Hence, no governance contest or board nomination pressure is expected. From a compliance standpoint, both entities correctly identify their legal classifications and provide required joint-filing exhibits. Investors should monitor future amendments: a switch to Schedule 13D or an increase above 10 % would materially change the governance outlook. Present impact: neutral-to-positive because of enhanced institutional oversight without activism.
Morgan Stanley e la sua controllata Morgan Stanley Capital Services LLC hanno presentato un Schedule 13G il 05/08/2025, dichiarando una partecipazione passiva combinata di 1.845.002 azioni ANAB (6,3% del capitale sociale) al 30/06/2025. La societ脿 madre riporta un potere di voto condiviso su 1.841.919 azioni e un potere dispositive condiviso su 1.845.002 azioni; non detiene alcun potere di voto o dispositive esclusivo.
La controllata possiede individualmente 1.525.502 azioni (5,2%) con poteri di voto e dispositive pienamente condivisi. La comunicazione 猫 stata effettuata secondo la Regola 13d-1(b), classificando Morgan Stanley come societ脿 madre/controllore (HC, CO) e la controllata come broker-dealer (BD, CO). Entrambe certificano che le azioni sono state acquisite nell鈥檕rdinaria attivit脿 aziendale e non con l鈥檌ntento di influenzare il controllo di AnaptysBio.
Morgan Stanley y su subsidiaria Morgan Stanley Capital Services LLC presentaron un Schedule 13G el 05/08/2025, revelando una participaci贸n pasiva combinada de 1,845,002 acciones ANAB (6,3% del total en circulaci贸n) al 30/06/2025. La empresa matriz reporta poder de voto compartido sobre 1,841,919 acciones y poder dispositive compartido sobre 1,845,002 acciones; no posee autoridad exclusiva de voto ni dispositiva.
La subsidiaria posee individualmente 1,525,502 acciones (5,2%) con poder de voto y dispositive completamente compartido. La presentaci贸n se realiza bajo la Regla 13d-1(b), clasificando a Morgan Stanley como empresa matriz/persona controladora (HC, CO) y a la subsidiaria como broker-dealer (BD, CO). Ambas certifican que las acciones fueron adquiridas en el curso ordinario de negocios y no con el prop贸sito de influir en el control de AnaptysBio.
氇贝 鞀ろ儬毽�鞕� 攴� 鞛愴殞靷� Morgan Stanley Capital Services LLC電� 2025雲� 8鞗� 5鞚检棎 Schedule 13G毳� 鞝滌稖頃橃棳 2025雲� 6鞗� 30鞚� 旮办 齑� 1,845,002 ANAB 欤检嫕鞚� 靾橂彊鞝� 氤挫湢 歆�攵�(鞝勳泊 氚滍枆 欤检嫕鞚� 6.3%)鞚� 瓿店皽頄堨姷雼堧嫟. 氇殞靷� 旄§潃 1,841,919欤检棎 雽�頃� 瓿惦彊 鞚橁舶甓�瓿� 1,845,002欤检棎 雽�頃� 瓿惦彊 觳橂秳甓�鞚� 氤搓碃頄堨溂氅�, 雼弲 鞚橁舶甓岇澊雮� 觳橂秳甓岇潃 氤挫湢頃橃 鞎婌姷雼堧嫟.
鞛愴殞靷姅 臧滊硠鞝侅溂搿� 1,525,502欤�(5.2%)毳� 鞕勳爠頌� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇溂搿� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞚措矆 鞝滌稖鞚� 攴滌箼 13d-1(b)鞐� 霐半澕 鞚措（鞏挫鞙茧┌, 氇贝 鞀ろ儬毽姅 氇殞靷�/韱奠牅鞛�(HC, CO)搿�, 鞛愴殞靷姅 欷戧皽-霐滊煬(BD, CO)搿� 攵勲霅╇媹雼�. 鞏戩浮鞚� 頃措嫻 欤检嫕鞚� 鞝曥儊鞝侅澑 靷梾 瓿检爼鞐愳劀 旆摑霅橃棃鞙茧┌ AnaptysBio鞚� 歆�氚瓣秾鞐� 鞓來枼鞚� 氙胳箻旮� 鞙勴暅 氇╈爜鞚� 鞎勲嫎鞚� 歃濍獏頃╇媹雼�.
Morgan Stanley et sa filiale Morgan Stanley Capital Services LLC ont d茅pos茅 un Schedule 13G le 05/08/2025, d茅clarant une participation passive combin茅e de 1 845 002 actions ANAB (6,3 % des actions en circulation) au 30/06/2025. La soci茅t茅 m猫re rapporte un pouvoir de vote partag茅 sur 1 841 919 actions et un pouvoir discr茅tionnaire partag茅 sur 1 845 002 actions ; elle ne d茅tient aucun pouvoir de vote ou discr茅tionnaire exclusif.
La filiale d茅tient individuellement 1 525 502 actions (5,2 %) avec un pouvoir de vote et discr茅tionnaire enti猫rement partag茅. Le d茅p么t est effectu茅 en vertu de la r猫gle 13d-1(b), classant Morgan Stanley comme soci茅t茅 m猫re/personne contr么lante (HC, CO) et la filiale comme courtier-n茅gociant (BD, CO). Les deux certifient que les actions ont 茅t茅 acquises dans le cours normal des affaires et non dans le but d鈥檌nfluencer le contr么le d鈥橝naptysBio.
Morgan Stanley und seine Tochtergesellschaft Morgan Stanley Capital Services LLC haben am 05.08.2025 einen Schedule 13G eingereicht, in dem sie einen kombinierten passiven Anteil von 1.845.002 ANAB-Aktien (6,3 % der ausstehenden Aktien) zum 30.06.2025 offenlegen. Die Muttergesellschaft meldet gemeinsames Stimmrecht 眉ber 1.841.919 Aktien und gemeinsames Verf眉gungsrecht 眉ber 1.845.002 Aktien; sie besitzt keine alleinigen Stimm- oder Verf眉gungsrechte.
Die Tochtergesellschaft h盲lt einzeln 1.525.502 Aktien (5,2 %) mit vollst盲ndig gemeinsamem Stimm- und Verf眉gungsrecht. Die Meldung erfolgt gem盲脽 Regel 13d-1(b) und klassifiziert Morgan Stanley als Muttergesellschaft/Kontrollperson (HC, CO) und die Tochtergesellschaft als Broker-Dealer (BD, CO). Beide best盲tigen, dass die Aktien im normalen Gesch盲ftsverlauf erworben wurden und nicht zum Zweck der Kontrolle von AnaptysBio.
FAQ
How many AnaptysBio (ANAB) shares does Morgan Stanley own?
What percentage of AnaptysBio鈥檚 outstanding stock is held by Morgan Stanley?
When was the ownership position effective?
Under which SEC rule was the Schedule 13G filed?
Does Morgan Stanley intend to influence control of AnaptysBio?
What are the classifications of the reporting persons?
